Drug Profile
Research programme: ophthalmic neuropathy therapeutic - Synovo
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Synovo
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Eye-disorders in Germany
- 26 Jul 2016 Early research in Eye disorders in Germany (unspecified route)